CClinicalTrials.gg
Sign In
RecruitingNCT06188234Updated Feb 15, 2024

The Prescription Patterns and Clinical Efficacy of Tenero Tab/Tenero M SR Tab

An observational study in Diabetes Mellitus, Type 2, sponsored by Hanlim Pharm. Co., Ltd.. Recruiting at 1 site in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2024-02-15.

Sponsored by Hanlim Pharm. Co., Ltd. · Observational

From the registry’s dates

  • Primary completion was expected by Jun 2026, 4 months ago, but the record still lists the study as recruiting.
  • Started Dec 2022; still recruiting 3 years 9 months later.
Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
3,000
Ages
19 Years and older
Sex
All
01

Study summary

This study is to observe the prescription patterns and clinical efficacy of patients prescribed with Tenero Tab/Tenero M SR Tab for diabetes treatment in routine clinical practice.

Read the detailed description

This study is to observe the clinical efficacy by analyzing the prescription patterns in routine clinical practice and changes in HbA1c, FPG, PP2G, etc., of patients prescribed with Tenero Tab/Tenero M SR Tab for diabetes treatment. Additionally, the study intends to assess patient satisfaction based on these observations.

02

Conditions studied

  • Diabetes Mellitus, Type 2

Keywords

  • Metformin HCI
  • Teneligliptin hydrochloride
03

In context

Diabetes Mellitus

10,925 studies on the registry are indexed under Diabetes Mellitus; 1,319 are open to participants now.

This study's planned enrollment of 3,000 is above the median of 233 across 2,220 observational studies indexed under Diabetes Mellitus.

Browse Diabetes Mellitus studies →

Lead sponsor

Hanlim Pharm. Co., Ltd. is the lead sponsor of 49 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Sampling method
Probability sample

Study population

Patients prescribed Tenero Tab/Tenero M SR Tab for diabetes treatment.

Inclusion criteria

  1. Adults over 19 years of age
  2. Individuals diagnosed with type 2 diabetes.
  3. Individuals who, at the clinical discretion, are prescribed Tenero Tab or Tenero M SR Tab for the purpose of diabetes treatment for the first time.
  4. Individuals who have voluntarily provided written consent to participate in this study.

Exclusion criteria

Exclusion Criteria:

  1. Pregnant or breastfeeding women.
  2. Individuals who are contraindicated according to the approved indications of Tenero Tab/Tenero M SR Tab.
  3. Other cases where the principal investigator and study personnel deem individuals ineligible for participation in this clinical trial.
05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
3,000 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Change in HbA1c at 6 months of prescribing Tenero Tablet/Tenero Emextended Release Tablet compared to baseline

    Change in HbA1c at 6 months of prescribing Tenero Tablet/Tenero Emextended Release Tablet compared to baseline

    Time frame: after 6 months of prescription for Tenero Tab/Tenero M SR Tab compared to baseline

07

Study locations

1 of 1 sites recruiting
  • Cheonan Endo Medical Clinic
    Cheonan, Korea, Republic of
    • Seokgi Yoon · Contact · 82-41-592-7201
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06188234
Lead sponsor
Hanlim Pharm. Co., Ltd.
Responsible party
Sponsor
First posted
Jan 3, 2024
Start date
Dec 27, 2022
Primary completion
Jun 2026 (estimated)
Completion
Jun 2026 (estimated)
Last update
Feb 15, 2024

Study contacts

Yeonhwa Kim
Contact
yh@hanlim.com
82-2-3489-6163
Seokgi Yoon
principal investigator · CHEONAN ENDO MEDICAL CLINIC

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Diabetes Mellitus→

Other studies from this sponsor

Hanlim Pharm. Co., Ltd.

Start the discussion